Literature DB >> 25541330

Matricellular protein periostin contributes to hepatic inflammation and fibrosis.

Yangmei Huang1, Weiping Liu1, Hongjun Xiao1, Alaiyi Maitikabili1, Qinghua Lin2, Tiantian Wu1, Zhengjie Huang3, Fan Liu4, Qi Luo3, Gaoliang Ouyang5.   

Abstract

Periostin actively contributes to tissue injury, fibrosis, atherosclerosis, and inflammatory diseases; however, its role in hepatic fibrosis is unclear. Herein, we revealed that periostin expression was significantly up-regulated in carbon tetrachloride- and bile duct ligation-induced mice with acute and chronic liver fibrosis. Deficiency in periostin abrogated the development of liver fibrosis in mice. Carbon tetrachloride treatment significantly increased α-smooth muscle actin, fibronectin, and collagen I levels in wild-type mice, which were unaffected in periostin-knockout mice. Periostin-deficient mice showed a significantly reduced area of collagen deposition and decreased levels of serum alanine aminotransferase and aspartate aminotransferase compared with wild-type mice after 2 weeks of carbon tetrachloride administration. Chemokine ligand 2, IL-6, IL-1β, tumor necrosis factor-α, and tissue inhibitor of metalloproteinases 1 mRNA levels were significantly lower in periostin-deficient mice than in wild-type mice after carbon tetrachloride treatment. Periostin colocalized with hepatic stellate cell-derived collagen I and α-smooth muscle actin in mouse acute and chronic fibrotic liver tissues. Transforming growth factor (TGF)-β1 markedly induced periostin expression in primary mouse hepatic stellate cells. Periostin-deficient mice showed significantly lower levels of TGF-β1 and TGF-β2 compared with wild-type mice after carbon tetrachloride treatment. High levels of periostin in patients with acute or chronic hepatitis correlated with TGF-β1 and TGF-β2 expression in serum from patients with hepatitis. Data indicate that periostin is a novel mediator of hepatic fibrosis development.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25541330     DOI: 10.1016/j.ajpath.2014.11.002

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Periostin on the road to nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  Endocrine       Date:  2015-11-19       Impact factor: 3.633

2.  Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds.

Authors:  Xinqiang Huang; Hong Cai; Ron Ammar; Yan Zhang; Yihe Wang; Kandasamy Ravi; John Thompson; Gabor Jarai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-08       Impact factor: 4.052

3.  Circulating periostin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Athanasios Papatheodorou; Panagiotis Kokkoris; Evangelos Terpos
Journal:  Endocrine       Date:  2016-10-13       Impact factor: 3.633

4.  Periostin promotes liver fibrogenesis by activating lysyl oxidase in hepatic stellate cells.

Authors:  Pradeep Kumar; Tekla Smith; Reben Raeman; Daniel M Chopyk; Hannah Brink; Yunshan Liu; Todd Sulchek; Frank A Anania
Journal:  J Biol Chem       Date:  2018-06-25       Impact factor: 5.157

Review 5.  Periostin as a multifunctional modulator of the wound healing response.

Authors:  John T Walker; Karrington McLeod; Shawna Kim; Simon J Conway; Douglas W Hamilton
Journal:  Cell Tissue Res       Date:  2016-05-28       Impact factor: 5.249

6.  Expression and clinical significance of periostin in oral lichen planus.

Authors:  Zhi-Rui Zhang; Li-Ya Chen; Hong-Yan Qi; Shao-Hua Sun
Journal:  Exp Ther Med       Date:  2018-04-03       Impact factor: 2.447

7.  Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.

Authors:  Katsunari Makino; Tomoko Makino; Lukasz Stawski; Julio C Mantero; Robert Lafyatis; Robert Simms; Maria Trojanowska
Journal:  J Invest Dermatol       Date:  2017-04-19       Impact factor: 8.551

8.  Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study.

Authors:  Jin-Zhou Zhu; Hua-Tuo Zhu; Yi-Ning Dai; Chun-Xiao Li; Zhi-Yun Fang; De-Jian Zhao; Xing-Yong Wan; Yu-Ming Wang; Fang Wang; Chao-Hui Yu; You-Ming Li
Journal:  Endocrine       Date:  2015-09-11       Impact factor: 3.633

Review 9.  Wound healing and fibrosis: a contrasting role for periostin in skin and the oral mucosa.

Authors:  Georgia Nikoloudaki; Kendal Creber; Douglas W Hamilton
Journal:  Am J Physiol Cell Physiol       Date:  2020-04-08       Impact factor: 4.249

10.  Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via αv integrin interaction.

Authors:  Akiko Sugiyama; Keishi Kanno; Norihisa Nishimichi; Shoichiro Ohta; Junya Ono; Simon J Conway; Kenji Izuhara; Yasuyuki Yokosaki; Susumu Tazuma
Journal:  J Gastroenterol       Date:  2016-04-04       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.